Less Ads, More Data, More Tools Register for FREE

Total Voting Rights

14 Feb 2012 15:00

RNS Number : 4147X
Hikma Pharmaceuticals Plc
14 February 2012
 



 

 

 

 

 

Hikma Pharmaceuticals PLC - Voting Rights and Capital

 

LONDON, 14 February 2012 Hikma Pharmaceuticals PLC (LSE: HIK) (NasdaqDubai: HIK) notifies the market that as at 31 January 2012 its capital consists of 195,862,507 ordinary shares with voting rights. There are no shares held in treasury.

 

The above figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, Hikma Pharmaceuticals PLC under the FSA's Disclosure and Transparency Rules.

 

- ENDS -

 

Enquiries:

 

Hikma Pharmaceuticals PLC

 

Henry Knowles

Company Secretary

 

+44 20 7399 2760

 

 

About Hikma

Hikma Pharmaceuticals PLC is a fast growing multinational group focused on developing, manufacturing and marketing a broad range of both branded and non-branded generic and in-licensed pharmaceutical products. Hikma's operations are conducted through three businesses: "Branded", "Injectables" and "Generics". Hikma's operations are based principally in the Middle East and North Africa ("MENA") region, where it is a market leader and sells across 17 countries, the United States and Europe. In 2010, the Group achieved revenues of $731 million (2009 $637 million) and profit attributable to shareholders was $99 million (2009 $78 million).

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TVREASALFEEAEFF

Related Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Back to RNS